99mTc-PSMA放射引导手术在复发性前列腺癌中的应用
共切除132份组织标本,其中58份病理证实转移,放射性评级灵敏度83.6%、特异度100%、准确率93.0%。中位随访13.8个月,13例持续生化无复发;中位随访12.2个月,20例持续免于治疗。
要点
- 99mTc-PSMA-RGS对转移灶检测灵敏度83.6%、特异度100%、准确率93.0%。
- 该技术可切除术前68Ga-PSMA-11 PET显示的全部病灶,并额外检出小至3mm转移灶。
- 术后41.9%患者持续生化无复发,64.5%持续免于治疗,长期影响待评估。
核心结论
- 99mTc-PSMA放射引导手术在复发性前列腺癌挽救性手术中可行,对术中检测和切除转移灶有较高价值。
- 该技术对结局的长期影响尚需进一步评估。
研究设计与样本
- 静脉注射99mTc-PSMA后行 gamma 探针术中放射引导的挽救性手术,平均活度571 MBq,平均至手术时间19.7小时。
- 将切除组织的放射性评级(阳性 vs 阴性)与术后组织病理学分析进行比较。
主要发现
- 共切除132份组织标本,其中58份组织学分析显示转移受累。
- 基于标本的放射性评级灵敏度为83.6%(CI:70.9-91.5%),特异度为100%,准确率为93.0%(CI:85.5-96.7%)。
- 99mTc-PSMA-RGS可切除术前68Ga-PSMA-11 PET显示的所有病灶,并在2例患者中检出小至3mm的额外转移灶。
- 13例患者出现手术相关并发症(Clavien-Dindo 1级12例,3a级1例)。
- 20例患者PSA降至0.2 ng/ml以下;中位随访13.8(范围4.6-18.3)个月,13例持续生化无复发;中位随访12.2(范围5.5-18.3)个月,20例持续免于治疗。
关键数值与推荐
- 放射性评级基于标本的灵敏度83.6%(CI:70.9-91.5%)、特异度100%、准确率93.0%(CI:85.5-96.7%)。
- PSA降至0.2 ng/ml以下见于20例患者。
- 中位随访13.8个月时13例生化无复发,中位随访12.2个月时20例免于治疗。
临床怎么用
- 对于根治性前列腺切除术后68Ga-PSMA-11 PET提示复发的患者,可考虑采用99mTc-PSMA-RGS行挽救性手术以术中定位并切除转移灶。
- 术中gamma探针放射引导有助于检出术前影像显示及额外的细小转移灶。
局限性
- 随访时间较短,中位随访分别为13.8个月和12.2个月。
- 该技术对长期结局的影响尚未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) can visualize metastatic lesions in recurrent prostate cancer (PC). However, reliable identification of small and/or atypically localized lesions during salvage surgery procedures is challenging. OBJECTIVE: To describe the technique, feasibility, and short-term outcomes of 99mTechnetium (99mTc)-based PSMA-radioguided surgery (99mTc-PSMA-RGS) for removal of recurrent PC lesions. DESIGN, SETTING, AND PARTICIPANTS: Thirty-one consecutive patients with evidence of recurrent PC on 68Ga-PSMA N,N'-bis[2-hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-N,N'-diacetic acid (68Ga-PSMA-11) PET after radical prostatectomy undergoing 99mTc-PSMA-RGS were retrospectively analyzed. SURGICAL PROCEDURE: Salvage surgery with intraoperative radioguidance using a gamma probe was performed after intravenous application of 99mTc-PSMA investigation and surgery (mean activity 571 MBq, mean time to surgery 19.7h). MEASUREMENTS: Radioactive rating (positive vs negative) of resected tissue was compared with the findings of postoperative histopathological analysis. Best prostate-specific antigen (PSA) response without additional treatment was determined after 8-16 wk postoperatively. Biochemical recurrence- and treatment-free survival was evaluated. RESULTS AND LIMITATIONS: In total, 132 tissue specimens were removed, of which 58 showed metastatic involvement on histological analysis. On a specimen basis, radioactive rating yielded a sensitivity of 83.6% (confidence interval [CI]: 70.9-91.5%), a specificity of 100%, and an accuracy of 93.0% (CI: 85.5-96.7%). With 99mTc-PSMA-RGS, all lesions visualized on preoperative 68Ga-PSMA-11 PET could be removed. Moreover, 99mTc-PSMA-RGS detected additional metastases as small as 3mm in two patients. Thirteen patients suffered from complications related to surgery (Clavien-Dindo grade 1: 12 patients; grade 3a: one patient). A PSA reduction below 0.2 ng/ml was observed in 20 patients. Thirteen patients remained biochemical recurrence free after a median follow-up of 13.8 (range: 4.6-18.3) mo. Twenty patients continued to be treatment free after a median follow-up of 12.2 (range: 5.5-18.3) mo. CONCLUSIONS: As a new technique for surgical guidance, 99mTc-PSMA-RGS is feasible, and has been proved to be of high value for successful intraoperative detection and removal of metastatic lesions in PC patients scheduled for salvage surgery. Its long-term impact on outcome has to be evaluated. PATIENT SUMMARY: In this report, we evaluated a novel technique to identify metastatic lesions intraoperatively in patients with recurrent prostate cancer to facilitate surgical removal. After intravenous injection of radioactive molecules that specifically bind to prostate cancer cells that show increased expression of the prostate-specific membrane antigen, we were able to detect and remove these metastatic lesions during surgery. Following salvage surgery, 41.9% of patients remained biochemical recurrence free (median follow-up of 13.8 mo) and 64.5% continued to be treatment free (median follow-up of 12.2 mo).
引用
- Maurer T, Robu S, Schottelius M, et al. 99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer. Eur Urol. 2018. PMID: 29625755. doi:10.1016/j.eururo.2018.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。